Tuesday, November 17, 2026
Home News ACPN Gives Edo Consumer Protection Committee Chairman 24 Hours to Prove Camosunate...

ACPN Gives Edo Consumer Protection Committee Chairman 24 Hours to Prove Camosunate Ban Claim, Threatens Legal Action

The Association of Community Pharmacists of Nigeria (ACPN), National Body, has given the Chairman of the Edo State Consumer Protection Committee, Mr Osaro Culture Iyamu, a 24-hour ultimatum to provide evidence supporting his reported claim that Camosunate is a banned medicinal product in Nigeria or face possible legal action.

Advertisement
ELLEXSLEEVES APARTMENT
SHINAAYO 2027

The Association also demanded an immediate public retraction and apology should the committee chairman fail to substantiate the claim with authentic regulatory documents.

HOUSE OF REPRESENTATIVES

ACPN, in a strongly worded statement signed by its National Chairman, Pharm. Ambrose Igwekamma Ezeh, MAW, and National Secretary, Obigariel Ikwu, described the alleged declaration as misleading, raising concerns over what it termed regulatory overreach and questionable enforcement practices by the Edo State Consumer Protection Committee.

The Association acknowledged the importance of efforts to eliminate counterfeit, adulterated, substandard and expired medicines from the Nigerian market but insisted that such interventions must be based on verifiable evidence, professional competence and strict compliance with relevant laws.

It specifically challenged Iyamu to produce an authentic notice from the National Agency for Food and Drug Administration and Control (NAFDAC) prohibiting, suspending, withdrawing or cancelling the registration of the particular Camosunate formulation he reportedly declared banned.

According to the Association, a check of NAFDAC’s official Greenbook showed that Camosunate Children Powder, with Registration Number 04-7908, manufactured by Front Pharmaceuticals PLC and marketed by Geneith Pharmaceuticals Limited, remains an actively registered medicinal product.

It stated that the product’s registration was approved on November 26, 2025, and is valid until November 25, 2030.

Describing the registration details as an official regulatory record, ACPN maintained that the committee chairman must provide documentary evidence to contradict the information rather than make public declarations without substantiation.

The Association further expressed concern over the reported enforcement operation at ALSO CARE Pharmacy in Evbuodia community, along Airport Road, Benin City, and the allegations subsequently made against the establishment.

It called for the public disclosure of the products allegedly seized, their registration details and independent regulatory evidence establishing that the medicines were counterfeit, prohibited or otherwise unlawful.

ACPN insisted that no pharmacy should be subjected to public condemnation based on unverified allegations.

On the legal authority of the committee, the Association cited Sections 22, 31 and 32 of the Pharmacy Council of Nigeria (Establishment) Act 2022, which provide the framework for pharmaceutical premises registration, inspection and enforcement through designated Pharmaceutical Inspection Officers.

It also referenced Sections 7 and 8 of the Counterfeit and Fake Drugs and Unwholesome Processed Foods (Miscellaneous Provisions) Act, Cap C34, Laws of the Federation of Nigeria 2004, which provide for the constitution and powers of State Task Forces.

According to ACPN, the powers conferred by the relevant legislation cannot automatically be exercised by an ordinary State Consumer Protection Committee without proof of the requisite legal constitution and appointments.

The Association also cited Section 5 of the NAFDAC Act, Cap N1, Laws of the Federation of Nigeria 2004, stressing that the agency has statutory responsibility for regulating medicinal products and that a general consumer-protection mandate does not automatically confer specialised pharmaceutical regulatory powers.

Consequently, ACPN outlined six demands, including the immediate production of authentic NAFDAC documentation establishing the alleged ban on Camosunate and a public retraction and apology if the claim cannot be substantiated.

It also demanded that the Edo State Government disclose the legal instrument establishing the Consumer Protection Committee, alongside any Federal Ministerial appointment or approval recognising it as a State Task Force under Section 7 of the Counterfeit and Fake Drugs Act.

Other demands include an immediate halt to pharmaceutical enforcement activities without demonstrable statutory authority and respect for the distinct regulatory responsibilities of NAFDAC and the Pharmacy Council of Nigeria.

The Association appealed to Edo State Governor, Senator Monday Okpebholo, to intervene urgently and ensure institutional accountability, warning that continued jurisdictional disputes could undermine public confidence in the state’s healthcare delivery system.

Reaffirming its commitment to protecting Nigerians from dangerous medicines, ACPN cautioned that consumer protection must not become a justification for misinformation, administrative arbitrariness or regulatory intimidation.

It maintained that public officials must be accountable for their statements, regulatory authority must be established by law, and professional pharmacy practice must be protected within the framework of existing legislation.

The Association vowed to pursue every legitimate institutional and legal avenue to defend the interests of pharmacists and ensure compliance with the law.

LIBRA GOLD HIRING

LEAVE A REPLY

Please enter your comment!
Please enter your name here

WP Twitter Auto Publish Powered By : XYZScripts.com